Actinium Pharmaceuticals, Inc. Share Price & Technical Analysis
ATNM · $1.18 (0.00%)
Healthcare / Biotechnology
$1.18
0.00%
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular …
Price chart
Seasonality
May has 2 positive and 2 negative years (last 5 years shown)
9% return in May, -1% avg return in past 3 year May month.
-12% return in 2026, -39% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -14% | 0% | -17% | 10% | 9% | – | – | – | – | – | – | – | -12% |
| 25 | -8% | 0% | 33% | -6% | 0% | -7% | 14% | 13% | -11% | -12% | 0% | 0% | 16% |
| 24 | 4% | 57% | -8% | -1% | 5% | -9% | -5% | -71% | -5% | -5% | -22% | -7% | -68% |
| 23 | 10% | -18% | -3% | -5% | -7% | -11% | -4% | -14% | -3% | -5% | -18% | 13% | -65% |
| 22 | -10% | 0% | -4% | 18% | -7% | -17% | 2% | 43% | 6% | 80% | -15% | -4% | 91% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$40.76M
P/E ratio
—
52W high
$1.95
52W low
$0.95
Volume
69,308
Beta
-0.11
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Actinium Pharmaceuticals, Inc. share price today?
- Actinium Pharmaceuticals, Inc. (ATNM) last traded around $1.18 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ATNM have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ATNM. Download the app for real-time alerts.
- How can I analyze Actinium Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.